Unique Benefits Seen With CAR T in AL Amyloidosis

Heather J. Landau, MD, of Memorial Sloan Kettering Cancer Center, highlights 2 transformative clinical insights from the phase 1b/2 NEXICART-2 trial (NCT06097832) evaluating NXC-201, a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for patients with AL amyloidosis. The most striking and clinically impressive observation from the study was the rapid, dramatic improvement witnessed in the trial's sickest participants. Patients entering the study with heavily elevated serum free light chains and accelerating organ progression experienced profound clinical benefit almost immediately after their light chains were controlled.

Landau notes that this immediate turnaround is unique compared to any other standard therapeutic agent she has administered. Although cellular therapy does not clear preexisting systemic amyloid deposits from tissue, halting the continuous production of monoclonal proteins effectively “turns off the spigot” of toxic light chains. Eliminating this constant biochemical effect relieves acute organ stress, allowing patients with escalating, severe symptoms to stabilize and improve quite rapidly.

Beyond immediate clinical efficacy, the trial underscores the quality-of-life differences experienced by patients treated with a cellular approach. Standard amyloidosis therapies traditionally dictate continuous, long-term treatment regimens that tie individuals to oncology centers indefinitely, whereas CAR T-cell therapy alters this paradigm by offering a definitive “one-and-done” intervention.

However, Landau acknowledges that adopting this regimen requires an intensive upfront investment from the patient; in the current protocol, all individuals were hospitalized for a mandatory 10-day observation window following their initial infusion to guarantee safety. However, after navigating this brief inpatient commitment, patients can achieve complete responses that free them from the need for weekly or biweekly clinic visits. This represents an invaluable benefit for a population with aggressive, chronic disease.